FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to new aminotetraline derivatives of formula (I) and their physiologically tolerable salts. In formula,A means a benzene ring or a ring specified in a group consisting of a 5-merous ring,R means the group R1-W-A1-Q-Y-A2-X1-； R1 means hydrogen, C1-C6-alkyl, C3-C6-cycloalkyl-C1-C4-alkyl, halogenated C1-C6-alkyl, tri-(C1-C4-alkyl)-silyl-C1-C4-alkyl, C1-C6-alkoxy-C1-C4-alkyl, amino-C1-C4-alkyl, C3-C6-cycloalkyl, C2-C6-alkenyl, an optionally substituted phenyl, C1-C6-alkoxy, di-C1-C6-alkylamino, an optionally substituted 5 or 6-merous heterocyclyl containing 1-3 heteroatoms specified in nitrogen and/or oxygen or sulphur； W means a bond； A1 means a bond； Q means -S(O)2- or -C(O)-； Y means -NR9- or a bond； A2 means C1-C4-alkylene, or a bond； X1 means -O-, C1-C4-alkylene, C2-C4-alkynylene； R2 means hydrogen, halogen, or two radicals R2 together with the ring atom to which they are attached form a benzene ring； R3 means hydrogen. The other radical values are specified in the patent claim. The invention also refers to intermediate products for preparing the compounds of formula (I).EFFECT: compounds possess the properties of glycine transporter inhibitors, particularly GlyT1 and can find application in treating neurological and psychiatric disorders, such as dementia, bipolar disorder, schizophrenia, etc or for managing pain related to glycerinergic or glutamatergic neurotransmission dysfunction.20 cl, 2 tbl, 326 exИзобретение относится к новым аминотетралиновым производным формулы (I) и их физиологически переносимым солям. Соединения обладают свойствами ингибиторов транспортера глицина, в частности активности GlyT1, и могут найти применение при лечении неврологических и психиатрических расстройств, таких как деменция, биполярное расстройство, шизофрения и др., или при лечении боли, связанной с дисфункцией глицинергической или глутаматергической нейропередачи. В формуле (I)A обозначает бензольное кольцо или кольцо,
